Tyra Biosciences Inc(TYRA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.39 | Insider Own | 23.3% | Shs Outstand | 59.7M | Perf Week | 3.03% |
| Market Cap | 1.45B | Forward P/E | - | EPS next Y | -5.58% | Insider Trans | 0.01% | Shs Float | 45.8M | Perf Month | 0.29% |
| Enterprise Value | 1.10B | PEG | - | EPS next Q | -0.67 | Inst Own | 96.6% | Short Float | 20.75% | Perf Quarter | -34.24% |
| Income | -0.15B | P/S | - | EPS this Y | -31.94% | Inst Trans | 7.69% | Short Ratio | 10.9 | Perf Half Y | -38.1% |
| Sales | 0.00B | P/B | 3.55 | EPS next 5Y | -16.83% | ROA | -42.15% | Short Interest | 9.50M | Perf YTD | -19.86% |
| Book/sh | 5.93 | P/C | 4.09 | EPS past 3/5Y | -15.07% -55.76% | ROE | -45.31% | 52W High | -48.17% ($40.65) | Perf Year | 34.38% |
| Cash/sh | 5.15 | P/FCF | - | Sales past 3/5Y | - | ROIC | -41.41% | 52W Low | 57.83% ($13.35) | Perf 3Y | 84.34% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -33.9% | Gross Margin | - | Volatility(W/M) | 5.22% 4.83% | Perf 5Y | -5.9% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.13 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 14.91 | EPS Q/Q | -46.33% | Profit Margin | - | RSI (14) | 48.97 | Recom | 1.2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.91 | Sales Q/Q | - | SMA20 | 4.34% ($20.19) | Beta | 0.65 | Target Price | $47.45 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/4 | SMA50 | -7.07% ($22.67) | Rel Volume | 0.72 | Prev Close | $21.48 |
| Employees | 87 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -6.17% - | SMA200 | -29.47% ($29.87) | Avg Volume(3M) | 0.87M | Price | $21.07 |
| IPO | 2021/9/15 | Option/Short | Yes/Yes | Trades | 8123 | Volume | 624,393 | Change | -1.91% |
🧬 This is a U.S. clinical-stage biotech company developing precision targeted oncology therapies. Using a precision medicine platform that targets specific signaling pathways, it develops drug candidates aimed at cancer and skeletal disorders, pursuing a differentiated approach to overcome treatment resistance. The company is a biotech entering unmet medical need markets through its differentiated precision targeted oncology approach.
Over the past 1 year, roughly in the middle
48% below its 1-year high.
Traded less than usual. That is 72% of its average volume.
TYRA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -31.9% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -5.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
20.8% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #130 of 597 in the industry
Based on market cap of $1B.
LYCA#129 Lycia Therapeutics Inc $1B PER - TYRA#130 Tyra Biosciences Inc $1B PER - 
ANAB#131 AnaptysBio Inc $1B PER 7.5 
GHRS#132 GH Research PLC $1B PER - 
KRSA#133 Korsana Biosciences Inc $1B PER - 
FAQ
What kind of company is TYRA?
TYRA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TYRA?
The market cap of TYRA is approximately $1.4B, ranking 2,318 within its sector.
What is the 52-week high and low for TYRA?
TYRA has recorded a 52-week high of $40.65 and a low of $13.35.
